Latest News
Venus Remedies
Source Name: Venus Remedies

Venus Remedies Ties up With Teva for Anti-Cancer Drug to Enter Canadian Market for First Time

Aug 26, 2014   17:10 IST 
Chandigarh, Punjab, India
  • Venus will initially manufacture the drug at the Venus Medicine Research Centre, its research unit, for assisting Teva in registrations, after which the company will use its manufacturing capabilities to support Teva in enhancing business from this drug in Canada

 

  • While Teva will use the infrastructure and regulatory competence of Venus for the commercialisation of this anti-cancer product in Canada, this agreement will enable Venus to penetrate the Canadian market

 

Venus Remedies Limited, a leading research-driven pharmaceutical company, has entered into a collaborative agreement with Teva, the largest manufacturer of generic drugs in the world, for a blockbuster anti-cancer drug in the Canadian market. The high-potential drug is under patent protection till 2016.

 

Under this collaboration, Venus Remedies will be initially manufacturing the drug at the Venus Medicine Research Centre, its research unit, for assisting Teva in registrations. Thereafter, Venus will also use its manufacturing capabilities to support Teva in enhancing the business from this drug in the Canadian market.

 

Commenting on the achievement, Dr Manu Chaudhary, Joint Managing Director, Venus Remedies Limited and Director, Venus Medicine Research Centre, said, “We already have an agreement with Teva for two Cephalosporins in the European Union market. The signing of this deal for the Canadian market has further strengthened our relationship and widened the scope of our products. This agreement will enable Venus to penetrate the Canadian market for the first time, thus adding another territory to its quest for quality services. Teva will use the infrastructure and regulatory competence of Venus for the commercialisation of this anti-cancer product in the Canadian market.”

 

The current global anti-cancer market size is USD 130 billion with a share of USD 2.8 billion for this drug. The anti-cancer market size of Canada alone is $ 75-100 million. This association will help Venus capture a sizeable market share for this product in the first year of the arrangement.

 

The Good Manufacturing Practices (GMP) certification granted to Venus for the European Union is also valid for Canada, based on which the Venus infrastructure and regulatory competence will be used for the commercialisation of this blockbuster drug in the Canadian market.

 

The drug is widely used for the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer. These cancerous conditions have a market of more than $4 billion, which is estimated to increase to $5.4 billion by 2020, in the regulated markets of the United States, the United Kingdom, France, Germany, Italy, Spain and Japan.

 

About Venus Remedies:

Venus Remedies, headquartered in Panchkula, Haryana (India), is among the 10 leading fixed-dosage injectable manufacturers in the world. The company has three manufacturing units, in Panchkula, Baddi (both India) and Werne (Germany) and 11 overseas marketing offices, including a presence in the US and Germany.

The manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by EUROPEAN-GMP, WHO-GMP, Latin American GMP (INVIMA), Ukrainian GMP, Zimbabwe GMP, Uganda GMP, Syrian GMP, Columbian GMP, Kenya GMP, Yemen GMP, Saudi Arabian GMP and Iranian GMP, among others.

Venus Remedies has been ranked 107th in Asia (source: Bio Spectrum Asia) and among the 500 largest pharmaceutical manufacturing companies in the world (source: Plimsoll Worldwide Business Intelligence Report).

Venus has won over 102 patents for its innovative research products worldwide. The company has presence in 60 countries and covers more than 75 products.

About Venus Medicine Research Centre:

The Venus Medicine Research Centre (VMRC) located at Baddi, Himachal Pradesh, is a fully equipped interdisciplinary drug discovery and development centre, duly approved by the Department of Scientific and Industrial Research (DSIR), Government of India.

The VMRC is committed to developing therapeutics to meet the challenges of antimicrobial resistance, and has come up with many solutions. It has achieved significant breakthrough in small molecule research for developing products helpful in combating antimicrobial resistance, utilising novel targets and adjuvants which synergise with other antibiotics and minimising potential for resistance. Significant breakthroughs have been achieved by the VMRC in antibiotic adjuvant entities for notable resistance barriers like ESBLs, “plasmid encoded carbapenem resistant metalo-beta-lactamases”, methicillin-resistant staphylococcus aureus (MRSA), bacterial biofilms and C. difficile infection.

For further information, please contact:

Amardeep Singh Tiwana

Adfactors PR Pvt Ltd

9814046480

[email protected]


 
 
For press background on Venus Remedies

click here